IP
IndiaPulse

Godrej Agrovet Limited (GODREJAGRO)

Micro Cap

FMCG stocks · Micro cap · NSE

Godrej Agrovet Limited (GAVL) is a diversified Indian agri-business company with segments including Animal Nutrition, Oil Palm, Crop Care, Dairy, and Poultry. Its subsidiary, Astec LifeSciences, focuses on Crop Protection chemicals and CDMO. GAVL aims for volume-led growth, margin expansion, and a strategic shift towards value-added and branded portfolios.

₹644.85
-14.10 · -2.14%
Quote04 Sept, 03:59 pm IST
Fundamentals05 Sept 2026 · screener
Score05 Sept, 10:20 pm IST · v4.3-runtime-valuation
Tags15 Aug 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · FMCG P/E 36.0 (n=42)
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Mixed fundamentals, management trust is supportive, price trend is neutral, and recent execution is mixed.

Suggested next step
Research, do not rush
The four lenses are not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
FAIR VALUE
51

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
Healthy Trust
80

low confidence · 0/0 claims checked

Technical
Neutral
58

Timing lens: price trend and sector relative strength.

Result consistency
mixed
61

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 30 Jun 2026

Bad · 0/100

PAT -14% YoY · margin compression · Rev +9% YoY · +22% QoQ

Filed 05 Aug 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹2,855 Cr+9.2%+22.4%
EBITDA₹240 Cr-11.1%+72.7%
Operating margin8.0%-200 bps+200 bps
PAT₹128 Cr-14.1%+25.5%
PAT margin4.5%-122 bps+11 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business & thesis

Growth engines, tailwinds/headwinds, and risk radar from management commentary

Business and thesis

Where growth can come from, and what can break the case

Thesis intactReviewed 2026-06-02T20:25:33.057Z
Management commentary snapshot

GAVL delivered strong Q4 FY26 results with consolidated revenues up 9% YoY to INR 2,333 crores and PBT (ex-exceptional) up 16.8% YoY to INR 87 crores. Full-year revenues surpassed INR 10,000 crores, reflecting broad-based volume-led growth, disciplined margin management, and improved business mix.

GAVL's Q4 and FY26 performance, driven by volume growth in Animal Nutrition and Oil Palm, and Astec's turnaround, supports the long-term thesis. Management's strategic focus on value-added products, portfolio diversification in Crop Care, and capital allocation discipline are key, despite near-term input cost pressures in Dairy and monsoon uncertainty.

Growth engines

Animal Nutrition Volume-Led Growth

Animal Nutrition delivered strong Q4 volumes (+15% YoY), with cattle feed up 24%, supported by new products, favorable commodity positions, and cost optimization. Focus on East and Central India.

Oil Palm Area Expansion & Productivity

Concluded a landmark year with highest ever area expansion and all-time high oil extraction ratio. Expecting 'demographic dividend' as juvenile trees become productive.

Astec LifeSciences CDMO Focus

Astec continued strong turnaround momentum with EBITDA break-even in FY26. Robust Q4 revenue and EBITDA driven by higher volumes in CDMO category and improved capacity utilization.

Godrej Foods Branded & New Categories

Strategic shift towards branded offerings (salience >80%). Entry into new segments like momos and frozen chicken, aiming for double-digit volume growth in value-added pieces.

Capacity and execution

Oil Palm Area Expansion

The oil palm business concluded a landmark year in fiscal year '26, marked by highest ever area expansion. Next year we're gunning for even beating that record on area expansion.

Astec Capacity Utilization

Astec LifeSciences recorded robust year-on-year growth, driven by higher volumes led by the CDMO category, improved realizations, and better capacity utilization.

FY27 Capex Allocation

Overall capex requirements would be in the range of around INR 350-400 crores, with roughly 75% to 80% as growth capex. Approximately 50% of capex deployment is going towards oil palm business.

Tailwinds

Shift to Branded Animal Feed

Elevated milk procurement prices act as a positive trigger for shift from unbranded to branded compound feed business, as farmers see benefits of higher milk yield.

Oil Palm Price Correlation

Palm oil prices are strongly correlated with crude oil prices; if the Middle East war continues, it will probably be good for oil palm.

Quick Commerce for Frozen Chicken

Quick commerce provides a structural tailwind for the frozen chicken industry, aiding cold chain management and category creation.

Currency Depreciation for Exporters

Being a net exporter, currency depreciation could offer a mild positive benefit for Astec LifeSciences, providing a natural hedge to imports.

Headwinds

Geopolitical Uncertainty (Iran War)

The Iran war remains an overhang for the FY27 outlook, with its impact on palm oil prices and crop protection business being a variable.

Crop Care Inventory Carry Forward

The Crop Care business remained impacted in Q4 FY26 due to carry forward of inventory in the co-marketing channel, leading to lower volumes of in-house products.

Elevated Milk Procurement Costs

Creamline Dairy's profitability remained under pressure due to elevated milk procurement costs, though expected to cool down from Q2 FY27.

Below Normal Monsoons

Predictions for below normal monsoons (El Niño) could impact some businesses, with severity expected in August and September, though geographical impact is variable.

Risk radar

Geopolitical Impact on Commodities

The Middle East war's continuation could be bad for the crop protection business but good for oil palm, creating a mixed impact on Agrovet overall.

Monsoon Variability and El Niño

The severity and geographical playout of El Niño are difficult to predict, posing a variable risk to agricultural businesses, especially Crop Care.

Commodity Price Volatility

Outlook for palm oil prices is uncertain, being played quarter-to-quarter. Milk procurement prices are expected to normalize from Q2 FY27 but remain a pressure point.

Crop Care Portfolio Concentration

Historically, the Crop Care business was very centric on cotton herbicide and Gracia (chilies), making it vulnerable to bad seasons for these two crops.

Management accountability

What management said, and what results must prove

Management accountability

What management said, and what results must prove

Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.

Analyst reading lens
Compare BOTH

Q4 results are compared YoY to account for seasonality in agri-businesses. Full-year results provide a comprehensive view of strategic execution and the achievement of the INR 10,000 crore revenue milestone.

Sector KPIs management disclosed

Consolidated Revenue Growth

Consolidated revenues grew to INR 2,333 crores, reflecting a 9% year-on-year growth for Q4 FY26. Full year revenues reached INR 10,233 crores, representing a robust year-on-year growth of 9%.

PBT (ex-exceptional) Growth

Profit before tax excluding non-recurring and exceptional items increased by 16.8% to INR 87 crores for Q4 FY26. For the full year, PBT increased by 17.2% year-on-year to INR 569 crores.

Animal Nutrition Volume Growth

Animal Nutrition delivered another strong quarter with Q4 volumes growing 15% year-on-year, significantly ahead of industry growth. Cattle feed volumes increased sharply by 24%.

Oil Palm Extraction Ratio

The oil palm business concluded a landmark year in fiscal year '26, marked by all-time high oil extraction ratio. Q4 extraction ratio was 20.77%, up from 19.76% in Q4 FY25.

Management forward view

FY27 Growth Targets

Management targets early double-digit revenue growth and mid-teens PBT growth at a consolidated level for FY27, primarily driven by underlying volume growth.

Strategic Mindset Shift

The company is undergoing a fundamental shift from a commodity-centric thinking to a market-customer facing approach across all businesses, led by innovation and marketing.

Crop Care Portfolio Diversification

Crop Care is diversifying from a two-crop segment to a multi-crop, multi-segment product company (herbicide, insecticide, fungicide) over the next 5 years.

Shareholder Value & Capital Discipline

Management is evaluating the optimal structure for the chemicals business, assuring protection of minority shareholder interests. Will maintain stringent discipline on working capital and ROCE.

Thesis monitor

Numbers and claims to verify in the next filings

CheckpointCurrent evidenceWhat to verify next
Animal Nutrition Volume GrowthQ4 volumes grew 15% YoY, cattle feed up 24% YoY.Continued double-digit volume growth, especially in East and Central India, and sustained market share gains.
Oil Palm Area Expansion & YieldHighest ever area expansion in FY26, Q4 OER at 20.77%.Beating FY26 area expansion record in FY27 and the impact of 'demographic dividend' from maturing trees on overall yield.
Astec LifeSciences CDMO GrowthEBITDA break-even in FY26, strong Q4 growth driven by CDMO.Continued CDMO-led growth, fruition of early leads in the pipeline, and achieving ~20% top-line growth for the business.
Crop Care Portfolio DiversificationLaunched Ashitaka (maize herbicide) and TAKAI (multi-crop insecticide).Contribution of new products to revenue (expected 16-18% of business in FY27) and successful shift to a multi-crop, multi-segment portfolio.

Verification checkpoints are IndiaPulse research interpretation, not investment advice.

Technical timing lens

Trend score and candlestick chart

58Neutral

SMA20 +6.0% / mo · MACD +

Stock trend: 70
Sector RS: 40
Sector 3M: -3.3% vs Nifty -1.5%

Technical chart

GODREJAGROdaily · 1Y · AUTO+5.7%
Latest close ₹644.85 on 2026-09-04
Bar
-1.8%
RSI
63
MACD hist
6.90
52W pos
55%
2026-09-04O ₹657.00H ₹665.50L ₹638.70C ₹644.85Vol 3.1L sh
₹522.56₹567.88₹613.20₹658.52₹703.84644.852026-032026-06VolRSIMACD2026-032026-042026-062026-072026-09
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal

Daily technical trend read

Bullish setup

Trend is constructive — long-term uptrend intact. RSI 63.

  • Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
  • SMA20 rising (~5.7% over last month) — short-term momentum positive.
  • RSI(14) at 63 — rising, no extreme reading.
  • MACD above signal, histogram expanding — bullish momentum building.
  • 15% off 52W high · 27% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Valuation & score drivers

U-Score 51 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor

51U-SCORE
Financial Turnaround

Fundamental score breakdown

FAIR VALUE
Valuation3/30
Growth10/25
Quality14/20
Balance Sheet9/15
Cash Flow10/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
51

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

51/100 · FAIR VALUE

Positive drivers

  • FCF yield is supportive at 9.1%.
  • Piotroski is strong at 8/9.
  • Cash flow contributes 10/10 to the score.

Main drags

  • Fair-value margin of safety is negative at -42.0%.
  • Valuation is weaker at 3/30; verify the latest quarterly trend.
  • Growth is weaker at 10/25; verify the latest quarterly trend.
Sector valuation model

Consumer valuation: PE/PEG and brand-quality premium

Consumer franchises can deserve higher multiples, but only when growth quality supports them.

Consumer PE/PEG
Primary lens
PE and PEG relative to growth, ROE, margins, and brand strength.
Secondary checks
Volume growth, pricing power, distribution, same-store or category growth.
Main risk check
Premium valuation needs durable growth and margin resilience.
PE
26.4
PB
6.1
EV/EBITDA
13.2
ROE
20.9%
ROCE
19.2%
FCF Yield
9.1%
Debt/Equity
0.8
MoS
-42.0%
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 05 Sept 2026
v4.3-runtime-valuation
Final score
51
Previous: 51
Verdict
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
-42.0%
Previous: -42.0%

Score history

12 stored score snapshots. Latest stored move: -3 points.

05 Sept 2026
v4.3-runtime-valuation
62
51
54
54
54
54
54
54
54
54
54
51

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number
₹235.33
-174.0% MoS
Growth-justified P/E
19.6
Growth-justified Value
₹453.95
-42.0% MoS
PEG
2.06

Trust score

Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth

Trust Score
80Healthy Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Healthy Trust: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 73rd percentile within FMCG. No major sub-score weakness stands out.

High Trust Lite: Promoter holding is 67.8%. Key concern: 1/4 latest quarters had positive YoY PAT growth.

Computed 05 Sept 2026
management-trust-v1
155 docs text-extracted · 81 concalls text-extracted
Score band
Healthy Trust

Generally investable credibility. Look for weak sub-scores before increasing position size.

Relative rank
90th percentile

overall median 67 · FMCG: 73rd pctile, median 78 · Micro: 81st pctile, median 73

Evidence depth
Financial-only

155 documents have extracted text, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Healthy Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
89
strong · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
61
acceptable · quarterly consistency

Trust positives

  • Promoter holding is 67.8%.
  • Promoter pledge is zero.
  • FCF yield is 9.1%.
  • 7 years of positive FCF.

Trust risks

  • 1/4 latest quarters had positive YoY PAT growth.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Financials

Full fundamentals table and 10-year revenue / profit / ROE history

Fundamentals

Valuation

P/E
26.40
P/B
6.08
EV/EBITDA
13.17
Market Cap
12408.00Cr

Profitability

ROE
20.90%
ROCE
19.20%
ROA
6.90%
Dividend Y
1.71%

Growth (CAGR)

Revenue 5Y
10.00%
EPS 5Y
8.00%
Revenue 3Y
3.00%
EPS 3Y
23.00%

Balance Sheet

Debt/Equity
0.77
Interest Coverage
6.27×
Altman Z
4.49
Book Value
106.00

Cash Flow

FCF Yield
9.12%
FCF Positive Y
7/5
OCF
1281.00 Cr
EPS TTM
23.22

Shareholding

Promoter Hold
67.75%
Promoter Pledge
0.00%
Momentum 52W
54%

Financial History

Updated 5/9/2026

Revenue

₹ Cr
No data

Net Profit

₹ Cr
No data

Return on Equity

%
No data

Peers

Business-comparable names in FMCG, ranked by similarity

Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.